Daily Stock List
LCTI Low Carbon Tech Intl., Inc. (LWCTF)
PennyStocks24, Super Nova Stock Picks, Super Hot Penny Stocks, Penny Stock Pick Report, Penny Stock MoneyTrain, Liquid Tycoon, Penny Stock Pick Alert, Winning Penny Stock Picks, WePickPennyStocks, StockMister, and Penny Stock SMS Publisher reported today on LCTI Low Carbon Tech Intl., Inc. (LWCTF), and we are highlighting the Company as "One to Watch" next week here at the QualityStocks Daily Newsletter.
LCTI Low Carbon Technologies International, Inc. is a U.S- based diversified company that lists on the OTC Markets. The Company focuses on the Clean-tech, Construction, Energy, Environmental, Mining and Real Estate business sectors. LCTI utilizes these real estate assets and technologies in the development of clean-tech energy projects. In addition, the Company combines the technology licenses with the profitable operating businesses creating profitable clean-tech companies.
LCTI issues sub-licenses to third parties for each technology. In exchange for the technology licenses, the Company receives project equity and licensing royalties. LCTI has five proposed projects. These are Gulf Coastal Plains Wetland Mitigation Bank, LCTI Tidal Mitigation Bank Texas, a 400 Metric Waste to Energy Facility, Luka, Mississippi, a 400 Metric Waste to Energy Facility, Beaumont, Texas, and a 400 Metric Waste to Energy Facility, Campeche, MX.
A Mitigation Bank is a wetland, stream, or other aquatic resource area that has been restored, established, enhanced, or (in certain circumstances) preserved for providing compensation for unavoidable impacts to aquatic resources permitted under Section 404 or a similar state or local wetland regulation.
Earlier this month, LCTI Low Carbon Technologies announced that they increased their equity stake in Industrial Commercial Mechanical, LLC (ICM). This is while preparing for an anticipated approval from the U.S. Army Corps of Engineers (USACE) regarding LCTI's investment in the development of a Mitigation Bank along the Gulf Coast of Texas. ICM is an integral investment meant to complement ultimately LCTI's other subsidiaries, technologies and projects.
Today, LCTI announced that they secured a 43.5 percent stake in Northwest Critical Minerals, LLC (NCM), having potential values upward of half a billion dollars for LCTI shareholders. NCM is a Rare Earth Elements (REE) mining company.
On March 10, 2013, LCTI leveraged one of their technologies as consideration for a stake in NCM. The technology was independently valued at approximately $20M by prominent U.S. appraisal firm Marshall & Stevens. The NCM prospects are now undergoing a formal valuation.
We are tracking LCTI Low Carbon Tech Intl., Inc. (LWCTF) and we have them on our radar screens as "One to Watch" next week here at the QualityStocks Daily Newsletter.
LCTI Low Carbon Tech Intl., Inc. (LWCTF), closed Friday's trading session at $0.164, up 32.26%, on 2,258,276 volume with 424 trades. The average volume for the last 60 days is 111,938 and the stock's 52-week low/high is $0.02/$1.25.
Stornoway Diamond Corp. (SWY.TO)
We are highlighting Stornoway Diamond Corp. (SWY.TO), here at the QualityStocks Daily Newsletter.
Based in Longueuil, Quebec, Stornoway Diamond Corp. is a leading Canadian diamond exploration and development enterprise. Their flagship asset is the 100 percent owned Renard Diamond Project. This Project is on track to becoming the Province of Quebec's first diamond mine. The Renard Diamond Project is near the Otish Mountains in north-central Quebec. Stornoway Diamond's shares trade on the Toronto Stock Exchange and on the OTC Markets under the symbol "SWYDF".
In addition, Stornoway maintains an active diamond exploration program. They have advanced and grassroots programs in the most prospective regions of Canada. Their corporate vision is to build a world-class diamond mining company based on quality Canadian diamond projects supplying a growing global market.
The Renard Diamond Project benefits from a large and expanding resource, good mining conditions, strong social acceptance, a modest environmental footprint, and the development of direct-to-mine infrastructure under the sponsorship of Quebec's "Plan Nord". Quebec's Ministère des Ressources naturelles issued the Mining Lease for Renard on September 17, 2012. The Mining Lease represents the formal transference of mineral title from Quebec to Stornoway Diamond. The Mining Lease is valid for 20 years.
On November 16, 2011, a positive feasibility study was announced for the project. The basis of it was on Probable Mineral Reserves of 18.0 million carats representing 23.0 million tonnes at an average grade of 78 carats per hundred tonnes (cpht), after allowance for mining dilution and ore recovery, and at a weighted average diamond valuation of US$180/carat. The result was base case estimates of Net Present Value (NPV) of C$672 million at a 7 percent discount rate and Internal Rate of Return (IRR) of 18.7 percent before taxes and mining duties, and C$376 million and 14.9 percent after taxes and mining duties and a predicted 11-year mine life.
Yesterday, Stornoway Diamond provided the results of an independent valuation on the Renard 65 bulk sample diamonds recently recovered at the Renard Diamond Project. WWW International Diamond Consultants (WWW) utilizing their March 2013 price book undertook the valuation in Antwerp, Belgium. Highlights include an average price of US$250 per carat on the total Renard 65 parcel of 997 carats, and a diamond price model for Renard 65 of US$180 per carat, with a "High" sensitivity of US$203 per carat and a "Minimum" sensitivity of US$169 per carat. Highlights additionally include valuations of US$8,500 per carat and US$5,900 per carat on the two largest stones of 9.77 carats (G color) and 6.40 carats (F color) respectively.
Stornoway Diamond Corp. (SWY.TO), closed Friday's trading session at $0.62, down 3.12%, on 184,007 volume. The stock's 52-week low/high is $0.45/$0.99.
Solo International, Inc. (SLIO)
The Stock Scout, PennyStockClub, Penny Stock Pros, 1-2-3 Stock Alerts, Penny Stock Circle, and StockMarketQuote.us reported earlier on Solo International, Inc. (SLIO), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Henderson, Nevada, Solo International, Inc. is an exploration mining company that focuses on deposits of rare earth metals and rare earth elements (REEs). Solo has mineral claims totaling 120 hectares located in the mining friendly jurisdiction of Portland Township, Quebec. Rare earth elements are essential raw materials used in nearly all sustainable energy technologies and a broad array of defense applications. All of Solo International's properties are presently at the exploration stage in Quebec.
Solo is concentrating on the acquisition, exploration, production, development and potentially, the operation of mining properties in strategic bulk mineable industrial metals (such as REE's, Titanium and Phosphates) sectors of eastern Canada. The United States Geological Survey (USGS) has listed Rare Earth Oxides as one of 19 minerals or materials that the U.S. is 100 percent import dependent upon. Rare earth elements (REEs) are important for the manufacture of steel, autos, motors, glass and electronic components. This makes REEs a strategic material because China holds most of the worldwide production at 97 percent.
The Province of Quebec has what may be large deposits of apatite, the parent mineral for rare earth elements. Earlier assessments of a number of areas close to Notre Dame-de-la-Salette indicate recoverable deposits of apatite in a location previously mined in the late 1800's. This location has designation as Philadelphia. There are several other old mines near this location. These are McLaren, Lac Tamo, Craft, North Star and Chapleau.
In September 2012, Solo International announced the start of their phase one exploration program on their Philadelphia REE Prospect. The REE claims consist of 2 mineral claims totaling the aforementioned approximately 120 hectares.
In December 2012, Solo International announced that they received encouraging analytical results from samples taken from the previous apatite mine sites on their Philadelphia Property. The analysis indicates positive anomalies of light rare earth and heavy rare earth elements. The light rare earth elements are La, Ce, Pr, Nd, Pm, Sm, Eu and Gd. These elements are usually more frequent in REE deposits. The heavy rare earth elements are Tb, Dy, Ho, Er, Tm, Yb, Lu and Y. Heavy rare earths are usually present in lower quantity in REE deposits. They have a more important value than light rare earth elements.
Solo International, Inc. (SLIO), closed Friday's trading session at $0.0068, even for the day, on 3,000 volume with 2 trades. The average volume for the last 60 days is 2,181,594 and the stock's 52-week low/high is $0.005/$0.134.
Universal Bioenergy, Inc. (UBRG)
Stock Analyzer, pastwellness.com, Investor News Source, and Stock Alerts reported earlier on Universal Bioenergy, Inc. (UBRG), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Universal Bioenergy, Inc. is an independent diversified energy company. They market natural gas, petroleum, coal, and propane. In addition, the Company engages in the acquisition and development of existing or recently discovered oil and gas fields, leases and surface coalmines. The Company was formerly known as Palomine Mining, Inc. They changed their name to Universal Bioenergy, Inc. in October of 2007. Universal Bioenergy is based in Irvine, California.
The Company markets energy resources to the largest public utilities, electric power producers and local gas distribution companies in the U.S. These entities serve millions of commercial, industrial and residential customers.
Universal Bioenergy previously announced that their subsidiary NDR Energy Group's new Electric Power Division is operational and is preparing to begin marketing electric power. On February 12, 2013, the Company announced NDR Energy received final approval for their "Power Marketing License" from the Federal Energy Regulatory Commission (FERC). With that approval, NDR Energy could commence selling electric power right away. Universal Bioenergy forecasts that sales of electricity are projected to generate an estimated $96 to $384 million in additional revenue for the Company.
Last week, Universal Bioenergy announced that the Company's management team for their global coal division is in negotiations with many companies to arrange the logistics and transportation for the sales of coal to their Asia and Europe customers. The Company and their transportation consultants are negotiating terms and pricing with a number of railroad companies to ship the coal from the load-out facilities at the mines and transport it to the various seaport terminals.
Furthermore, last week, Universal Bioenergy announced that they are in advanced negotiations for an agreement with a company in China to sell them large quantities of high thermal steam coal for electric power production. The expectation is that the agreement will have provisions to grow coal sales from $108 to $270 million annually based on their increasing demand.
Universal Bioenergy's intention is to sell an estimated 1,200,000 to 3,000,000 tons of high-grade thermal steam coal annually for the next 3 years for export to the company in China. The total estimated amount of coal to undergo delivery for the next 3 years is 3,600,000 to 9,000,000 tons (at an estimated $90.00 per ton). The total estimated value of the transaction is $324 to $810 million over the next 3 years.
Universal Bioenergy, Inc. (UBRG), closed Friday's trading session at $0.0052, up 62.50%, on 52,515,129 volume with 337 trades. The average volume for the last 60 days is 7,845,539 and the stock's 52-week low/high is $0.0019/$0.0333.
Vidaroo Corp. (VIDA)
PennyStocks24, Wallstreetbuzz, Penny Stock Professor, StockHideout, Stock Roach, and Stock Exploder reported recently on Vidaroo Corp. (VIDA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Vidaroo Corp. is the provider of a unique cloud-based video distribution and syndication software platform. The Company's cloud-based video publishing technology enables their customers to easily create, deliver, as well as monetize video and advertising delivery. Vidaroo has their corporate headquarters in Altamonte Springs, Florida.
Current customers of Vidaroo come from diverse industries. These include advertising agencies, academic educational institutions, large churches, media companies, and corporate training organizations. Past clients of the Company include national brands - Microsoft, Coca-Cola Company, Tribune News Company, Toyota, Emmis Communications, Clear Channel, Black Eyed Peas, Justin Timberlake and others.
In 2009, Vidaroo launched their Software-as-a-Service (SaaS) based online video player. Now, it is moving forward as a feature-rich and intuitive video distribution and syndication platform. Its innovative capabilities include live-streaming, on-demand playback via channel creation, social media sharing and distribution, fully native ad rotation, and customizable player themes managed by self-service administrative controls.
Video programs undergo installation with a simple one line "embed code" that is easily applicable to any website destination. The Company's platform works well for on-demand and enterprise use, and the billing and signup processes are fully automated.
Last month, Vidaroo announced that they retained the services of three highly focused marketing agencies. Additionally they engaged other marketing assets to promote services for their target audiences with the intention of boosting sales in 2013.
Last week, Vidaroo announced that the Company has started an aggressive direct marketing campaign that will target faith-based organizations, academic education, corporate training, destination marketing, and sports-centered organizations. The marketing campaign will feature incentives to encourage customers to try Vidaroo's cloud-based video publishing technology.
Mr. Tom Moreland, Chairman and Chief Executive Officer of Vidaroo, said, "The direct marketing program has already been launched. We've sweetened our approach with incentives like the first 30-days free to get people to try the software and use their imagination."
Vidaroo Corp. (VIDA), closed Friday's trading session at $0.0057, up 83.87%, on 35,348,725 volume with 334 trades. The average volume for the last 60 days is 956,033 and the stock's 52-week low/high is $0.0028/$0.025.
Athersys, Inc. (ATHX)
BioTech Play reported recently on Athersys, Inc. (ATHX), Streetwise Reports and Greenbackers did earlier, and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Athersys, Inc. is a clinical stage biotechnology company that lists on the NASDAQ Capital Market. The Company engages in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Athersys is developing their MultiStem® cell therapy product. In addition, Athersys has developed a distinct portfolio that includes other technologies and product development opportunities. The Company has their corporate headquarters in Cleveland, Ohio.
Their MultiStem® cell therapy product is a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory, as well as immune disease areas. MultiStem® cell therapy has shown the ability to promote tissue repair and healing in an assortment of ways. This includes through the production of multiple therapeutic factors produced in response to signals of inflammation and tissue damage.
Currently, Athersys has numerous clinical stage programs involving MultiStem®. The Company has built strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies and world-renowned research institutions in the U.S. and Europe to develop their platform and products further. Athersys has built a strategic partnership with Pfizer, Inc. to develop MultiStem® for inflammatory bowel disease. The Company has also built a strategic partnership with RTI Biologics, Inc. to develop cell therapy for use with a bone allograft product in the orthopedic market.
This week, Athersys announced the recent publication of articles in two peer-reviewed scientific journals - Journal of Immunology and Circulation. The articles describe the potential for multipotent adult progenitor cells (MAPC(R)s), or MultiStem® cells, to provide benefit in autoimmune disease and in peripheral vascular disease (PVD), respectively.
Additionally, the articles describe specific biological mechanisms through which this cell therapy delivers benefit in these areas and illustrate the strong scientific foundation supporting MultiStem® cell therapy. These findings may support clinical investigation in these areas. They represent important, additional commercial opportunities for Athersys' MultiStem® franchise.
Athersys, Inc. (ATHX), closed Friday's trading session at $1.89, down 0.53%, on 1,813,376 volume with 3,700 trades. The average volume for the last 60 days is 760,053 and the stock's 52-week low/high is $0.95/$1.97.
Solar Energy Initiatives, Inc. (SNRY)
Penny Dreamers reported recently on Solar Energy Initiatives, Inc. (SNRY), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.
Listed on the OTC Markets' OTCQB, Solar Energy Initiatives, Inc. is a diversified provider of solar solutions. The Company focuses on large-scale projects as well as the distribution of solar products. Solar Energy Initiatives, together with their subsidiaries, markets and sells solar power products, systems, and services in the U.S. and the Caribbean.
Founded in 2006, the Company has their headquarters in Cary, North Carolina. The Company formerly went by the name NP Capital Corp. They changed their corporate name to Solar Energy Initiatives, Inc. in September of 2008. The Company is a Delaware Corporation.
Solar Energy Initiatives primarily designs, markets, and sells solar power systems for residential and commercial customers; and designs, markets, sells, owns, and operates solar power systems for municipal and commercial customers. In addition, they design, develop, and manage solar parks. The Company's products include photovoltaic panels, photovoltaic roofing systems, solar thermal products, balance of system products, as well as management system products.
Their SNRYPower subsidiary is a developer and manager of municipal and commercial scale solar projects. Their SNRYSolar, Inc. subsidiary is a wholesale distributor of branded photovoltaic and thermal (water heating) systems. These systems sell by way of a network of dealers throughout the United States and the Caribbean.
Solar Energy Initiatives is mainly concentrating their sales efforts in regions where electricity prices and government incentives are attractive and have sped up solar power adoption. The business segments that the Company has identified to go after can require a considerable level of expertise and capital. Presently, Solar Energy Initiatives has found a very good working business model; they are working with many states, counties, and banks that understand how to make the solar projects successful.
Furthermore, the Company has additionally pursued plans to acquire the assets of an entertainment consulting firm. They have not yet signed a definitive acquisition agreement. Moreover, the closing of any acquisition is contingent upon the Company raising funds sufficient to pay the purchase price.
Solar Energy Initiatives, Inc. (SNRY), closed Friday's trading session at $0.0018, up 200.00%, on 70,199,719 volume with 160 trades. The average volume for the last 60 days is 5,623,196 and the stock's 52-week low/high is $0.0004/$0.14.
VOIS, Inc. (VOIS)
PennyStocks24 reported this month on VOIS, Inc. (VOIS), MyBestStockAlerts, Penny Stock SMS Publisher, and StockMister did earlier, and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, VOIS, Inc. engages in the development of software and related hardware in the U.S. Based in San Diego, California, the Company is currently focusing their efforts on sales of thought-controlled technology software and the continued development of their proprietary EEG micro headset. On December 18, 2012, VOIS entered into a License Agreement with Mind Technologies, Inc. (MTEK); they secured a non-exclusive license to use and develop MTEK's existing thought-controlled software applications.
VOIS develops software applications using a wireless headset. This headset reads brainwaves and allows interaction with a computer using the power of their mind. The Company's thought-controlled software products in development include "Mind Mouse"; it allows the user to navigate the computer, click and double click to open programs, compose email, and send. Products in development also include "Master Mind" to allow users to play existing personal computer games.
In addition, products in development include Think-Tac-Toe. It allows users to play against the computer. VOIS also offers the wireless headset - a brain computer interface device that might be used to interpret electrical signals produced by the brain.
This past February, VOIS announced that they entered into a Letter of Intent (LOI) with Mind Technologies (MTEK). This is to purchase 100 percent of the assets of MTEK. VOIS has agreed to the acquisition so they can secure ownership of all Brain-Computer-Interface (BCI)/ thought-controlled technology developed and undergoing development by the Company. VOIS develops systems for the BCI market that includes state of the art EEG headset technology and software applications designed to operate with thought controlled technologies.
In March, VOIS provided a Mobile EEG Headset update. They completed the working prototype and tested the device on a number of Android models. The tests provided positive results as pertains to communicating with the devices and receiving the EEG signals from the brain. The product is now patent pending, with all necessary filings submitted and recorded at the United States Patent and Trademark Office (USPTO).
VOIS, Inc. (VOIS), closed Friday's trading session at $0.004, up 37.93%, on 30,591,964 volume with 196 trades. The average volume for the last 60 days is 5,608,603 and the stock's 52-week low/high is $0.0017/$0.099.
VIASPACE, Inc. (VSPC)
The QualityStocks Daily Newsletter would like to spotlight VIASPACE, Inc. (VSPC). Today, VIASPACE, Inc. closed trading at $0.0158, up 5.33%, on 233,920 volume with 14 trades. The stock’s average daily volume over the past 60 days is 857,941, and its 52-week low/high is $0.0013/$0.0158.
VIASPACE, Inc. (VSPC) is focused on growing renewable Giant King™ Grass as a low-carbon fuel for clean electricity generation and environmentally friendly energy pellets, as well as a feedstock for bio-methane production, green cellulosic biofuels, biochemical, and biomaterials. A high-yield, low-cost feedstock, Giant King Grass meets the cost targets of green energy applications while maintaining a carbon neutral profile.
The highest yielding biomass crop in the world, Giant King Grass can grow in a variety of soil conditions and does not compete with food crops. Once Giant King Grass is established, it can be harvested at 3-5 feet tall every 45 to 60 days or at 14 feet tall twice a year. This incredibly high rate of growth provides a continual supply of biomass year-round, enabling strategically located power plants to operate 24 hours a day regardless of the current season.
VIASPACE provides Giant King™ Grass seedlings and technical expertise to qualified projects. The company also plans to serve as a project developer or co-developer for power plant or pellet mill projects, together with local partners that have land and require electricity, heat, pellets, biogas, or biofuels. VIASPACE and its partners are capable of delivering an integrated Giant King Grass plantation and biomass power plant project in just 24 months.
The excellent energy characteristics of Giant King Grass and its ability to be harvested multiple times each year enable and energy output yield that is much higher than other crops . This superior feedstock offers material productivity benefits at remarkable costs for energy production, biofuels, and biomaterials. Giant King Grass is currently being grown in the United States, Virgin Islands, China, and other areas. Disclaimer
VIASPACE, Inc. Company Blog
VIASPACE, Inc. News:
VIASPACE Insiders Extend Lock-up of Shares
VIASPACE Chairman Interviews with CEONEWS.Tv Regarding Business Dynamics and Recent Corporate Milestones
VIASPACE Announces Contract With AGRICORP And Giant King Grass Growing In Nicaragua
Rafarma Pharmaceuticals, Inc. (RAFA)
The QualityStocks Daily Newsletter would like to spotlight Rafarma Pharmaceuticals, Inc. (RAFA). Today, Rafarma Pharmaceuticals, Inc. closed trading at $0.50, up 6.38%, on 790 volume with 3 trades. The stock’s average daily volume over the past 60 days is 3,986, and its 52-week low/high is $0.0501/$0.98.
Rafarma Pharmaceuticals, Inc. (RAFA) is a multiproduct pharmaceutical company specializing in the production of generic antibiotics and specialty pharmaceuticals, including its own proprietary products approved by the ministry of health. Rafarma stands as one of the most ambitious projects in recent medical history, having constructed the most technologically advanced pharmaceutical plant in Russia.
Based in Terbuny, Lipetsk region, Russia, Rafarma possesses a unique niche in the burgeoning pharmaceutical market and is poised to become a major player in the international drug industry. The company was established under the auspices of the Foundation to Support Health Care and has been approved by the Ministry of Health.
Rafarma recently received the general license for pharmaceutical products and began manufacturing three new products: Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Receiving the general license was one of the final steps the company needed to open its new plant in Terbuniv, and Rafarma has been named one of only four national strategic pharmaceutical suppliers to the Russian Federation.
Advances in health care science, medicine, and technology have increased the general life expectancy of Eastern European citizens steadily over the past decade. Elderly citizens, which comprise the largest portion of the pharmaceuticals market, have bolstered demand for pharmaceuticals nationwide. Rafarma is well positioned to capitalize on the expanding industry with its strong relationships and state-of-the-art production facility. Disclaimer
Rafarma Pharmaceuticals, Inc. Company Blog
Rafarma Pharmaceuticals, Inc. News:
Rafarma Pharmaceuticals, Inc. (RAFA) Announces Engagement of QualityStocks Investor Relations Services
Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
Rainbow Coral Corp. (RBCC)
The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.115, up 4.55%, on 141,272 volume with 13 trades. The stock’s average daily volume over the past 60 days is 169,534, and its 52-week low/high is $0.10/$2.67.
Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.
Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.
The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.
The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer
Rainbow Coral Corp. Company Blog
Rainbow Coral Corp. News:
RBCC Targets Companion Diagnostics Opportunities in Booming $232 Billion Personalized Medicine Market
RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow
RBCC TheraKine Joint Venture Offers Significant Opportunity in Licensing
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.0915, up 0.55%, on 410,072 volume with 170 trades. The stock’s average daily volume over the past 60 days is 301,351, and its 52-week low/high is $0.091/$0.295.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium Receives ISO Certification for Excellagen
Cardium's To Go Brands® to Launch Expanded VitaRocks® kids Vitamin Line With New Retail Distribution
Cardium's Excellagen® Awarded American Podiatric Medical Association Seal of Approval, Company Also Announces Addition of a Regional Distributor for Excellagen
Cardium Therapeutics, a medical technology company focused on cardiovascular and tissue repair, has developed and is implementing a comprehensive commercialization strategy for Excellagen, the company’s novel syringe-based gel to boost the healing process for all types of wounds, including diabetic ulcers, surgical wounds, trauma wounds, and chronic vascular ulcers. The product’s proven effectiveness, range of application, and ease of use has opened an extensive target market, which Cardium is addressing with a variety of partnership agreements.
In January 2013, Cardium announced a distribution agreement with Academy Medical to market, sell, and distribute Excellagen to U.S. government medical providers. Academy Medical has a growing customer base of over 35 VA and military hospitals within the U.S. Cardium also recently announced an agreement with an independent regional distributor group, consisting of ten sales representatives, to market, sell, and distribute Excellagen to podiatric and orthopedic physicians, plastic surgeons, hospitals, and surgical centers. They plan to enter into additional agreements to introduce Excellagen to a variety of regional markets while broadening its potential applications in wound care.
Cardium is also establishing strategic partnerships to cover the marketing and sale of Excellagen into U.S. vertical wound healing market channels, including: (1) podiatry, (2) wound care centers, hospitals, and long-term care facilities, (3) government agency providers (such as the U.S. Department of Veterans Affairs, Bureau of Indian Affairs, and military hospitals), (4) dermatology and plastic surgery, and (5) orthopedic surgery. This is a proven approach similar to other companies in the advanced wound care space.
Cardium is also actively pursuing a reimbursement process for Excellagen with Centers for Medicare & Medicaid Services and private insurance providers. Already-established standard CPT procedure reimbursement codes may apply when Excellagen is used with surgical debridement procedures and through the DRG reimbursement system for in-hospital surgical procedures, as well as in long-term care facilities and through their service providers.
Internationally, Cardium plans to obtain a CE Mark for the potential marketing and sale of Excellagen in the 27-country European Union, and expects to obtain a CE Mark for Excellagen in the second quarter of 2013. The company also has a marketing and distribution agreement with BL&H Co. for the marketing and sale of Excellagen in South Korea, which is currently advancing through the regulatory and reimbursement pricing process. In addition, Advanced Biosciences Research, an affiliate of bioRASI, is assisting Cardium for the planned commercialization of Excellagen in Russia and the eight additional member countries comprising the Commonwealth of Independent States (CIS).
For additional information, visit www.CardiumTHX.com
International Stem Cell Corp. has scored a major goal in the use of stem cells for the treatment of Parkinson’s disease. Parkinson’s is a debilitating disorder, involving a progressive degeneration of dopamine producing neurons in the central nervous system. Traditional treatments simply attempt to replace the lost dopamine, which can help at first but, as symptoms grow worse, its efficacy declines, leaving many patients severely disabled.
In a recent study, positive animal data reported by ISCO has established that Parkinson’s symptoms can be successfully treated with the company’s unique parthenogenetic stem cell derived neuronal cells, a huge accomplishment. Previous moves to treat Parkinson’s with implanted neuronal cells involved cells from human fetuses, which presents ethical issues. In addition, fetal neuronal cell transplantation causes a movement disorder known as dyskinesia in some patients.
ISCO’s parthenogenetic pluripotent human stem cells are derived from unfertilized eggs, avoiding the use or destruction of viable human embryos. Such cells can be a source of therapeutic cells for hundreds of millions of individuals with minimal immune rejection. ISCO Executive VP of Business Development, Dr. Simon Craw, commented that ISCO is the only company with this technology, and maintains a broad intellectual property portfolio with strong patent protection.
The tests, reported by ISCO researchers at the American Academy of Neurology, showed that animals treated with the cells moved more normally, consistent with cell survival and the release of dopamine, and that dopamine was being produced months after treatment. The study also found that many of the injected stem cells remained as neurons and provided a type of neuroprotection in the brain. In addition, no adverse events, including dyskinesia, deformations, tumors, or overgrowth, were observed in the treatment groups.
Dr. Evan Snyder, co-author of the study and director of the Stem Cells and Regenerative Biology Program at Sanford Burnham Medical Research Institute, says the pilot study represents a “first essential step in bringing cell-based therapies for Parkinson’s disease to clinical trials.” ISCO has submitted a preclinical plan to the FDA, outlining additional safety and toxicology studies remaining to be done, with the goal of beginning human testing in 2014.
Besides Parkinson’s disease, ISCO’s other therapeutic programs include metabolic liver diseases and cornea transplants.
For additional information, visit www.InternationalStemCell.com
World Energy Solutions, a leading energy management services firm and approved energy services provider in the TIPS/TAPS purchasing program, today announced that the company has successfully procured over 62 million kWh of electricity for Abilene Independent School District (AISD), a public school district serving over 17,000 students in Abilene and Impact, Texas.
Abilene ISD was able to test market prices for various electricity terms and products in an efficient and transparent manner through a series of online auctions run on the World Energy Exchange®. The competitive event attracted twelve suppliers overall, who submitted more than 120 bids fir AISD’s business in a period of one hour. Resulting in a new 36-month electricity contract, the auction is expected to save the school district more than $1.4million. Under the new contract terms, delivery is slated to begin June 2014.
“With our existing electricity contract in force through May 2014, World Energy helped us get aggressive and proactively price the market to find and secure a great rate for our future energy needs,” commented Scott McLean, Associate Superintendent of Operations, Abilene Independent School District. “World Energy was able to attract a dozen energy suppliers to compete for our business. Building on that participation, the transparency of the online auction helped us see how the suppliers priced the various products and terms we were interested in, while the structure of the auctions drove participants to deliver their best prices.
“I really appreciate how transparent and data-driven World Energy’s process is. I saw every bid submitted by every supplier; could easily calculate savings based on relevant comparisons; and had all the documentation on hand at the conclusion of the auction to make a quick and informed buying decision. In addition, we were able to leverage World Energy’s TIPS/TAPS contracting vehicle for this procurement, which made it easy for us to take our energy requirements out to market. Previously we relied on energy brokers to forward a recommendation to us without actually seeing for ourselves how the bids came in. I can say with great confidence that World Energy’s online auction process is a big improvement and left no doubt decisions were made based upon actual market conditions.”
Brian Dafferner, Vice President of ERCOT at World Energy Solutions, stated, “Teaming with Abilene ISD to deliver great results for the school district is an important win for World Energy and a bellwether procurement in the State of Texas. The AISD electricity procurement showcases the power and value of our online auction approach: twelve bidders, 120+ bids in one hour, total transparency. That’s a new paradigm for Texas energy buyers, one that should shake up the status quo.”
World Energy’s Texas operations include offices in Dallas, Fort Worth, and Houston, with additional sales personnel throughout the State. For more information on World Energy Solutions, visit www.worldenergy.com.
StemCells, a company engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced that it has reached an agreement with the California Institute for Regenerative Medicine (CIRM) for CIRM to extend approximately $19.3 million in funding for preclinical development and IND-enabling activities of the company’s proprietary HuCNS-SC® product candidate (purified human neural stem cells) for Alzheimer’s disease. The funding will be granted in the form of a forgivable loan and was awarded within CIRM’s Disease Team Therapy Development Award program (RFA 10-05) in September 2012. The research is aimed towards filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration within four years.
“With CIRM’s support, we are now able to lay the groundwork that could result in the world’s first neural stem cell trial in Alzheimer’s patients,” commented Martin McGlynn, President and CEO of StemCells, Inc. “Currently, there are no good treatment options for Alzheimer’s patients, and there aren’t any on the horizon, so it is clear that the field could benefit from creative approaches to this devastating and challenging disease. Our collaborators at UC Irvine have provided a compelling preclinical rationale to test the utility of our cells to restore memory in patients afflicted with this deadly condition.”
StemCells will test its HuCNS-SC cells, in a joint effort with researchers at the University of California, Irvine (UCI), as a potential treatment for Alzheimer’s disease. The research team at UCI is led by the impressive pairing of Frank LaFerla, Ph.D., a world-renowned researcher in the field, and Matthew Blurton-Jones, Ph.D. Dr. LaFerla is Director of the Institute for Memory Impairments and Neurological Disorders (UCI MIND), and Chancellor’s Professor, Neurobiology and Behavior. Dr. Blurton-Jones is Assistant Professor, Neurobiology and Behavior, at UCI.
Dr. Blurton-Jones delivered a presentation in July 2012 at the Alzheimer’s Association Annual Meeting showing data that demonstrated the company’s neural stem cells restored memory and dramatically improved synaptic function in two animal models. An important characteristic of the data is that achieving the positive results did not require a reduction in beta amyloid or tau that accumulates in the brains of Alzheimer’s patients and are responsible for the pathological hallmarks of the disease.
Loan funds are expected to be disbursed periodically over the four-year project period, with disbursements subject to a number of preconditions, including the achievement of certain progress milestones and compliance with certain financial covenants. The term of the loan is ten years, but may be extended under certain circumstances. The loan is unsecured and will bear interest at the one year LIBOR rate plus two percent; however, the interest rate will increase by one percent each year after year five. The loan is forgivable, such that the company’s obligation to repay the loan will be contingent upon the success of HuCNS-SC cells in Alzheimer’s disease. No warrants will be issued in connection with the loan, but the Company will owe various success milestone payments in the event of the product’s commercial success.
For further information, please visit www.stemcellsinc.com
Today's Top 3
The QualityStocks Public Company Sponsor News